Journal of Clinical Immunology

, Volume 1, Issue 2, pp 90–93 | Cite as

Impaired antibody responses to a pneumococcal polysaccharide vaccine in patients with non-Hodgkin's lymphoma in remission

  • Oscar F. Ballester
  • Muhammad Shurafa
  • Howard Toben
  • Kapisthalam S. Kumar
  • C. Lynne Burek
Original Articles


Eight patients with non-Hodgkin's lymphoma who have been in complete clinical remission for a mean of 23.3 months were evaluated for their antibody responses to a pneumococcal vaccine. The results were correlated with lymphocyte subpopulations, serum immunoglobulin levels, andin vitro mitogenic responses to phytohemagglutinin, concanavalin and pokeweed mitogen. Two patients with normal antibody responses had immunoglobulin levels and mitogenesis within the range of controls. Impaired antibody responses in the remaining six patients were correlated either with marked depressed mitogenesis to phytohemagglutinin or with low levels of IgA. Impaired humoral immune responses seem to persist in these patients even after several months of sustained clinical remission.

Key words

Lymphoma immunity antibodies vaccine pneumococcal 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jones S, Griffith K, Dombrowski P, Gaines J: Immunodeficiency in patients with non-Hodgkin lymphomas. Blood 49:335–344, 1977Google Scholar
  2. 2.
    Amlot P, Green L: Serum immunoglobulins G, A, M, D and E concentrations in lymphomas. Br J Cancer 40:371–379, 1979Google Scholar
  3. 3.
    Saslow S, Carlisle H, Bouroncle B: Antibody response in hematologic patients. Proc Soc Exp Biol Med 106:654–656, 1961Google Scholar
  4. 4.
    Papac R: Lymphocyte transformation in malignant lymphomas. Cancer 26:279–286, 1970Google Scholar
  5. 5.
    Feld R, Bodey G: Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 39:1018–1025, 1977Google Scholar
  6. 6.
    Steele R, Han T: Effects of radiochemotherapy and splenectomy on cellular immunity in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma. Cancer 42:133–139, 1978Google Scholar
  7. 7.
    King G, Grozea P, Eyre H, LoBuglio A: Neoantigen response in patients successfully treated for lymphoma. Ann Intern Med 90:892–895, 1979Google Scholar
  8. 8.
    Sokal J: Measurement of delayed skin-test responses. N Engl J Med 293:501–502, 1975Google Scholar
  9. 9.
    Toben H, Smith R: T lymphocytes bearing complement receptors in a patient with chronic lymphocytic leukaemia. Clin Exp Immunol 27:292–302, 1977Google Scholar
  10. 10.
    Voller A, Bidwell D, Huldt G, Engvall E: A microplate method of ELISA and its application to malaria. Bull WHO 209–221, 1974Google Scholar
  11. 11.
    Siber GR, Weitzman SA, Aisenberg AC, Weinstein HJ, Schiffman G: Impaired antibody response to pneumococcal vaccine following treatment for Hodgkin's disease. N Engl J Med 299:442–448, 1978Google Scholar
  12. 12.
    Addiego JE, Ammann AJ, Schiffman G, Baehner R, Higgins G, Hammond D: Antibody response to pneumococcal polysaccharide vaccine (PPB) administered before treatment of patients with Hodgkin's disease (HD). Blood 54 (Suppl. 1):177a, 1979Google Scholar
  13. 13.
    Louie S, Schwartz R: Immunodeficiency and the pathogenesis of lymphoma and leukemia. Semin Hematol 15:117–138, 1978Google Scholar

Copyright information

© Plenum Publishing Corporation 1981

Authors and Affiliations

  • Oscar F. Ballester
    • 1
  • Muhammad Shurafa
    • 1
  • Howard Toben
    • 1
  • Kapisthalam S. Kumar
    • 1
  • C. Lynne Burek
    • 1
  1. 1.Department of Medicine, Division of Hematology, and Department of ImmunologyWayne State University, and Harper-Grace HospitalDetroit

Personalised recommendations